test3

Find A Clinical Trial

Disease Type: Head and Neck

Trial ID IO102-IO103-022
Sponsor ID IO Biotech

A Phase 2 Multi Arm (Basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with Pembrolizumab as First-Line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, or Metastatic Urothelial Bladder Cancer

Trial ID SGN-PDL1V
Sponsor ID SGNPDL1V-001

A Phase 1 Study of SGN-PDL1V in Advanced Solid Tumors

Trial ID PRT3645
Sponsor ID PRT3645-01

A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors

Trial ID MCLA-129
Sponsor ID MCLA-129-CL01

Phase 1/2 Dose Escalation and Expansion Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors

Trial ID INBRX-109
Sponsor ID Ph 1 Ph 2 INBRX-106

An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Multicohort, Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors

Trial ID HFB-200301
Sponsor ID HFB-200301-01

A Phase 1a/1b, Open-Label, Multi-Center, Dose Escalation and Expansion Study of HFB200301 (TNFR2 Agonist Antibody) as a Single Agent and in Combination With Tislelizumab (Anti-PD-1 Antibody) in Adult Patients With Advanced Solid Tumors

Trial ID GCT1042
Sponsor ID GCT1042-01

A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects With Malignant Solid Tumors

Trial ID DK210 (EGFR)
Sponsor ID DEKA Biosciences

Dose-finding Phase 1 Trial: Evaluating Safety and Biomarkers Using DK210 (EGFR) for Inoperable Locally Advanced and/or Metastatic EGFR+ Tumors With Progressive Disease Failing Systemic Therapy

Trial ID AZD9592
Sponsor ID D9350C00001

A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumors

Trial ID ABBV-514 +ABBV-181
Sponsor ID M21-410

A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors With ABBV-514 as a Single Agent and in Combination With Pembrolizumab or Budigalimab